Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
NCT03060720 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 271
Last updated 2026-03-30
Summary
This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations
Conditions
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH - lead OTHER
Principal Investigators
-
Matthew B Yurgelun, MD · Dana-Farber Cancer Institute
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-02-24
- Primary Completion
- 2019-04-07
- Completion
- 2028-02-29
Countries
- United States
Study Locations
More Related Trials
-
Predicting Effective Therapy in Pancreatic Cancer
NCT03033927 ·Status: ACTIVE_NOT_RECRUITING
-
Optical and Biochemical Biomarkers in Early Pancreatic Cancer
NCT03404661 ·Status: COMPLETED
-
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
NCT06574620 ·Status: RECRUITING ·Phase: NA
-
Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
NCT00805688 ·Status: COMPLETED
-
Influence of Metastatic Sites on Survival Outcomes and Predictive Factors for Extended Survival in Metastatic Pancreatic Cancer a Retrospective Study
NCT07086352 ·Status: NOT_YET_RECRUITING
-
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
NCT02478892 ·Status: RECRUITING
-
Identification of Biomarkers for Early Detection of Pancreatic Cancer
NCT00897494 ·Status: COMPLETED
-
Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer
NCT07326150 ·Status: ACTIVE_NOT_RECRUITING
-
Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery
NCT00900016 ·Status: COMPLETED
-
Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer
NCT00826982 ·Status: COMPLETED
-
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
NCT02869802 ·Status: RECRUITING
-
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
NCT00005926 ·Status: COMPLETED ·Phase: PHASE2
-
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
NCT05356039 ·Status: RECRUITING
-
A Clinical Study of BRCA and DNA Damage Repair Genes in Blood Samples of Chinese Pancreatic Cancer Patients
NCT05138302 ·Status: UNKNOWN
-
Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants
NCT00898482 ·Status: COMPLETED
-
Blood Markers of Early Pancreas Cancer
NCT03568630 ·Status: RECRUITING
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT06122896 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Identification of Immunogenic Neo-epitopes for the Development of Personalised Pancreatic Cancer Vaccines
NCT04379960 ·Status: COMPLETED
-
A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma
NCT01983410 ·Status: ACTIVE_NOT_RECRUITING
-
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
NCT06151223 ·Status: RECRUITING
-
Cancer Stem Cell Specific Aptamer's Ability to Detect Blood Circulating Cancer Stem Cells and Its Role as a Predictor of Prognosis in Pancreatic Cancer
NCT05745415 ·Status: COMPLETED
-
Pancreatic Cancer Screening for At-risk Individuals
NCT05006131 ·Status: RECRUITING
-
A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
NCT03250078 ·Status: RECRUITING
-
Pancreatic Cancer Early Detection Program
NCT02206360 ·Status: ACTIVE_NOT_RECRUITING
-
Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer
NCT00593008 ·Status: TERMINATED ·Phase: PHASE1